证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 1 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | |------------| | | | 投资者关系 | | 活动类别 | | | | | | | | 参与人员 | | | | | 时间 2024 年 8 月 8 日 地点 线上沟通 上市公司接 董事长、总经理：董凡 董事、副总经理：唐先敏 待人员姓名 董事、财务总监：廖雪云 董事会秘书：黄聪 一、公司简要介绍 2024 年半年度经营情况 2024 年上半年，公司实现营业收入 14.96 亿元，较去年同期增长 47.77%； 其中各种血液灌流器、吸附器产品实现销售收入 14.01 亿元，同比增长 87.35%。 投资者关系 实现归属于上市公司股东的净利润 5.53 亿元，较去年同期增长 99.10%；实现 活动主要内 扣除非经常性损益的净利润 5.26 亿元，同比增长 99.99%。报告期内，公司整 容介绍 体毛利率为 80.54%，其中血液灌流器产品毛利率为 84.46%，具备强劲的盈利 能力和市场竞争力。经营活动产生的现金流量净额为 7.49 亿 ...

Investment Rating - The report maintains a rating of "Buy" for the company [3][8]. Core Views - The external policy environment has improved, leading to good development trends in nephrology, hepatology, and critical care business segments. The company's internationalization progress is also on track [2]. - The company achieved a revenue of 1.496 billion yuan in H1 2024, representing a year-on-year increase of 47.77%. The net profit attributable to shareholders was 553 million yuan, up 99.10% year-on-year [8]. - The report forecasts EPS for 2024, 2025, and 2026 to be 1.06 yuan, 1.35 yuan, and 1.72 yuan respectively, with a target price of 36.60 yuan, corresponding to a PE ratio of 35x for 2024 [8]. Financial Performance - In H1 2024, the company reported a gross margin of 80.54%, benefiting from cost reduction and efficiency improvements. The operating cash flow was 749 million yuan, an increase of 71.58% [8]. - The company’s revenue from the nephrology segment grew by 84% year-on-year, with significant sales increases in various product lines [8]. - The international sales revenue increased by 64% year-on-year in H1 2024, with products being used in over 2,000 hospitals across 94 countries [8]. Business Development - The nephrology field saw advancements in product positioning and disease management, with notable sales growth in blood purification products [8]. - The hepatology segment reported a 112% increase in sales revenue, driven by the promotion of a dual plasma molecular adsorption system [8]. - The critical care segment also experienced a 72% increase in sales revenue, with new products being adopted in over 100 hospitals [8].

主持人您好 您这边可以发言了 能听到吗?能听到,我已经上线了大哥您开始吧 好的,各位投资者,大家下午好,我是华泰证券的一二首席戴文,欢迎大家参加电凡生物的2024年的中贸易与交流会。本次会议由我们华泰证券与中金箭头证券、国信证券、西南证券、国金证券以及国投证券六家券商 现在呢昨天发布了24年的半年报我们看到了整体上半年实现了非常亮眼的业绩啊二季度不管是收入还是利润的增长都有了进一步的提速我们本次的会议呢也是特别荣幸的请到了公司的豪华高管团队进行解读包括了董事长兼总经理董丹先生然后副总经理唐芊怡女士工作董事及财务总监廖云雪女士以及公司的董事会秘书 黄冲黄总那么我就先介绍这么多下面先进入会议的第二个环节有请公司的董事长董总开场发言然后有请黄总介绍上半年的经营亮点下面我们就把时间交给管理层董总跟黄总有请大家好我是剑凡生物的董凡非常高兴跟各位在线上做一个交流 首先要感谢今天组织交流会的六家券商的朋友华泰证券中信箭头西南证券国金证券国信证券国投证券感谢你们对我们公司长期以来的关心然后也非常感谢今天上线的线上我们交流的各位投资机构的朋友们 希望通过今天这个线上的交流能够大家对我们剑藩生物多一些了解据我们自己的看法现在剑藩 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1]. Core Views - The company has demonstrated significant revenue growth, with a 48% year-on-year increase in revenue for the first half of 2024, reaching 1.496 billion RMB, and a 99% increase in net profit attributable to shareholders, amounting to 553 million RMB [1]. - The sales of blood perfusion products in the renal field grew by 84% year-on-year, with the HA130 blood perfusion device sales increasing by 67% and sales volume up by 127% [1]. - The company maintains a high level of R&D investment, amounting to 113 million RMB, which is 7.54% of its revenue, and has received 16 new patent authorizations [1]. - The company has achieved EU MDR certification for its main products, which is expected to accelerate overseas market expansion [1]. - New product iterations and expansion into new application areas are anticipated to contribute to long-term growth [1]. Summary by Sections Performance Overview - In the first half of 2024, the company achieved revenue of 1.496 billion RMB, a 48% increase year-on-year; net profit attributable to shareholders was 553 million RMB, up 99%; and the net profit excluding non-recurring items was 526 million RMB, also up 100% [1][3]. Business Analysis - The sales of blood perfusion products in various fields are growing rapidly, with significant increases in both revenue and sales volume across renal and liver products [1]. - The company’s overseas sales revenue increased by 64%, indicating a positive external environment and strategic development trends [1]. R&D and Product Development - The company invested 113 million RMB in R&D, representing 7.54% of its revenue, and has a total of 359 authorized patents [1]. - The HA series blood perfusion devices and BS series plasma bilirubin adsorbers have received EU MDR certification, marking a significant achievement in compliance with new regulations [1]. Profit Forecast and Valuation - The company is expected to achieve revenues of 3.347 billion RMB, 4.444 billion RMB, and 5.630 billion RMB for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 74%, 33%, and 27% [1]. - The forecasted net profit attributable to shareholders for the same period is 985 million RMB, 1.330 billion RMB, and 1.714 billion RMB, with growth rates of 126%, 35%, and 29% [1].

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, achieving a total of RMB 500 million, representing a growth of 25% year-over-year[6]. - The company's operating revenue for the reporting period was ¥1,495,624,529.80, representing a 47.77% increase compared to ¥1,012,143,747.49 in the same period last year[12]. - The net profit attributable to shareholders was ¥552,505,833.05, a 99.10% increase from ¥277,508,333.27 year-on-year[12]. - The net cash flow from operating activities reached ¥749,267,980.24, up 71.58% from ¥436,698,486.81 in the previous year[12]. - Basic earnings per share increased to ¥0.69, a 97.14% rise compared to ¥0.35 in the same period last year[12]. - The overall gross margin for the reporting period was 80.54%, with blood purification products achieving a gross margin of 84.46%[41]. - The company reported a significant increase in income tax expenses, totaling ¥109,496,807.52, a 103.29% rise compared to the previous year[52]. - The company achieved a net cash flow from operating activities of ¥749,267,980.24, a 71.58% increase year-on-year[52]. - The company reported a total comprehensive income of ¥569,582,116.03 for the first half of 2024, compared to ¥272,005,374.12 in the previous year, showing a growth of about 109%[147]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[6]. - A strategic acquisition of a local competitor is anticipated to enhance the company's product offerings and increase market penetration[6]. - The company has established collaborations with over 80 major hospitals for clinical application research, enhancing its market position[34]. - The company has launched a dedicated continuous blood purification circuit for the DX-10, receiving Class III medical device registration in August 2023, with sales initiated in March 2024[46]. - The company established 28 medical alliances as part of the "Navigation Plan 3.0," which includes 28 demonstration center hospitals and 500 new practice centers[42]. - The company’s marketing efforts in the nephrology sector have expanded to over 6,000 hospitals, enhancing patient management and treatment options[41]. Research and Development - Research and development expenses have increased by 30% to RMB 50 million, reflecting the company's commitment to innovation[6]. - The company invested 113 million yuan in R&D, accounting for 7.54% of total revenue, and holds 27 medical device registration certificates, with 24 being Class III[34]. - The company is actively involved in research and development of new technologies and products to enhance treatment options for critical conditions such as organophosphate poisoning and severe liver diseases[19]. - The company employs a combined research and development model, focusing on both independent and collaborative R&D efforts to enhance technological capabilities[22]. - The company has developed core technologies for blood perfusion devices, including carrier preparation, coating, ligand, and medical-grade purification processes, achieving industry-leading purification levels[35]. Product Development and Innovation - New product launches are expected to contribute an additional RMB 100 million in revenue, with a focus on innovative blood purification technologies[6]. - The company has developed a range of innovative blood purification products, including disposable blood perfusion devices and plasma bilirubin adsorbers, targeting various medical conditions[19]. - The DX-10 blood purification machine is recognized as one of the "Fifth Batch of Excellent Domestic Medical Equipment Products"[21]. - The Future F20 blood purification device supports multiple blood adsorption treatment modes and received EU CE certification in 2021[21]. - The company has reported non-recurring gains totaling ¥26,621,349.95, primarily from government subsidies and asset disposals[17]. Financial Management and Investments - The company plans to invest RMB 200 million in new manufacturing facilities to boost production capacity by 40%[6]. - The company has ongoing significant non-equity investments, with a cumulative actual investment amount of ¥152,920,596.98[63]. - The company has a total of 203,000 in various financial investments, with expected returns ranging from 2.60% to 3.10%[69]. - The company has a total of ¥30,000,000 in entrusted management with CITIC Bank Zhuhai Branch, yielding an expected annual return rate of 3.50%[67]. - The company has not engaged in derivative investments for hedging or speculative purposes during the reporting period[70]. Risk Management - The company has identified potential risks related to regulatory changes and market competition, with strategies in place to mitigate these risks[1]. - The company is closely monitoring regulatory changes in the medical device industry to adapt its business strategies accordingly, minimizing risks associated with policy shifts[79]. - The company emphasizes the importance of R&D investment to keep pace with industry advancements and to avoid obsolescence of existing products[77]. Corporate Governance and Social Responsibility - The board has decided not to distribute cash dividends for this fiscal year, opting to reinvest profits into growth initiatives[1]. - The company made cash donations of ¥15.8 million for public welfare projects in the first half of 2024[53]. - The company has received several awards for its contributions to charity and social responsibility, including the "China Red Cross Contribution Medal" and the "Outstanding Contribution Award" from the Zhuhai Federation of Industry and Commerce[91]. - The company has not faced any significant environmental penalties or issues during the reporting period, as it is not classified as a key pollutant discharge unit[90]. Shareholder Information - The company has implemented employee stock ownership plans, with 5,642,150 shares held by key personnel, representing 0.70% of total equity[87]. - The company completed a share repurchase plan, acquiring 24,242,904 shares at a total cost of approximately RMB 499.997 million, with a maximum price of RMB 24.93 per share and a minimum price of RMB 15.89 per share[111]. - The total number of shares outstanding is 807,555,312, with 35.44% being restricted shares and 64.56% being unrestricted shares[110]. - The largest shareholder, Dong Fan, holds 43.98% of the shares, amounting to 355,131,867 shares[116]. - The company has not issued any new shares or made any changes to the shareholding structure during the reporting period[113].

证券代码：300529 证券简称：健帆生物 公告编号：2024-071 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2024 年 5 月 20 日 召开了 2023 年度股东大会，审议通过了《关于修订＜公司章程＞的议案》，鉴于 公司回购注销 2021 年限制性股票激励计划未能解禁的第一类限制性股票 10.40 万股，使得公司总股本相应减少 10.40 万股，公司总股本从 80755.5312 万股减少 至 80745.1312 万股，公司注册资本由 80755.5312 万元减少至 80745.1312 万元。 近日，公司完成了工商登记变更及《公司章程》备案，并取得了珠海市市场 监督管理局换发的《营业执照》。具体相关信息如下： 一、基本情况 1、名称：健帆生物科技集团股份有限公司 2、统一社会信用代码：914404006175105107 3、类型：其他股份有限公司（上市） 4、法定代表人：董凡 5、注册 ...

特别提示： 1、本次完成回购注销的限制性股票共计 104,000 股，占回购前健帆生物科 技集团股份有限公司（以下简称"公司"）总股本的 807,555,312 股的 0.0129%， 涉及激励对象 5 人。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司已于 2024 年 8 月 1 日办理完成上述限制性股票的回购注销手续。 3、本次限制性股票回购注销完成后，公司总股本由 807,555,312 股变更为 807,451,312 股。 4、因公司本次股份变动数量占公司总股本的比例很小，经计算，本次限制 性股票回购注销完成后，"健帆转债"的转股价格不变，仍为 39.62 元/股。 证券代码：300529 证券简称：健帆生物 公告编号：2024-065 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于部分限制性股票回购注销完成暨不调整健帆转债转股 价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本激励计划简述 1、2021 年 2 月 4 日公司召开第四届董事会第十次会议，审议通过了《关于 公司<2021 ...

证券代码：300529 证券简称：健帆生物 公告编号：2024-064 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次注销期权数量共计 2,154,250 份：其中注销 2022 年股票期权激励计 划首次授予部分尚未行权的股票期权 1,885,250 份；注销 2022 年股票期权激励计 划预留授予部分尚未行权的股票期权 269,000 份。 2、本次期权注销不会对公司的股本造成影响。 健帆生物科技集团股份有限公司于 2024 年 7 月 19 日召开第五届董事会第 二十次会议和第五届监事会第十五次会议，审议通过了《关于注销部分股票期权 的议案》，鉴于公司 2022 年股票期权激励计划第二个行权期公司层面业绩考核 目标未达成及部分激励对象因个人原因离职，同意公司根据相关规定注销股票期 权数量共计 2,154,250 份：其中注销 2022 年股票期权激励计划首次授予部分尚未 行权的股票期权 1,885,250 份，涉及 559 名激励 ...

| 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2024-060 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 第五届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 健帆生物科技集团股份有限公司（以下简称"公司"）第五届监事会第十五 次会议于 2024 年 7 月 19 日在公司会议室以现场会议及通讯表决的方式召开，本 次会议应出席监事 3 人，实际出席监事 3 人。本次会议通知提前以电子邮件及电 话通知等方式向全体监事送达，会议由监事会主席彭小红先生主持，会议的召开 符合《中华人民共和国公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事认真讨论，审议并表决通过了以下议案： 1、审议通过了《关于调整股票期权行权价格和限制性股票授予及回购价格 的议案》 经审议，监事会认为：鉴于公司 2023 年度权益分派方案已实施完毕，公司 董事会根据股东大会的授权及《2021 年限制性股票激励计划（草 ...

健帆生物科技集团股份有限公司 关于作废部分已授予尚未归属的第二类限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300529 | 证券简称：健帆生物 公告编号：2024-063 | | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | 健帆生物科技集团股份有限公司（以下简称"公司"） 2024 年 7 月 19 日召 开第五届董事会第二十次会议和第五届监事会第十五次会议，审议通过了《关于 作废部分已授予尚未归属的第二类限制性股票的议案》，同意公司 2021 年限制 性股票激励计划部分第二类限制性股票予以作废，现将相关事项说明如下： 一、本激励计划简述 1、2021 年 2 月 4 日公司召开第四届董事会第十次会议，审议通过了《关于 公司<2021 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2021 年限制性股票激励计划实施考核管理办法>的议案》和《关于提请公司股东大会 授权董事会办理 2021 年限制性股票激励计划相关事宜的议案》。公司独立董事 对此发表了独立意见，律师等中介机构出具 ...